CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 294,878 enrolled
Drug / intervention
Probenecid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04746989
NCT04746989N/ACompleted
CompareCT.gov

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines- Probenecid vs Allopurinol

Brigham and Women's Hospital·observational·Posted Feb 10, 2021·Updated Feb 27, 2026

In Brief

An observational study evaluating Probenecid and Allopurinol for Gout. Completed, enrolled 294,878 participants across 1 site.

Detailed Summary

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesUnited States
CollaboratorsNational Institute on Aging (NIA), Rutgers University, Johns Hopkins University

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedFeb 10, 2021
Enrollment StartFeb 1, 2021
Primary CompletionJul 17, 2023
Study CompletionDec 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 5.4 years ago

Interventions

Probeneciddrug

Probenecid claim is used as the exposure group.

Allopurinoldrug

Allopurinol claim is used as the reference group.